Claims for Patent: 10,316,078

Summary for Patent: 10,316,078

Title:	Serotype cross-reactive, dengue neutralizing antibody and uses thereof
Abstract:	Disclosed are isolated antibodies, or antigen binding fragments thereof, that bind to dengue virus epitopes, as well as kits containing them, compositions containing them, and passive vaccines comprising them, in one embodiment, the antibody or antigen binding fragment thereof is capable of binding to a whole dengue virus particle better than binding to a dengue virus surface glycoprotein. Also disclosed are methods of using the antibodies or antigen binding fragments thereof, nucleic acids encoding them, vectors expressing the nucleic acids, host producing them, and methods of manufacturing them.
Inventor(s):	Cheng-I Wang, Katja Fink, Paul MACARY, Roland ZUEST, Meihui XU
Assignee:	Agency for Science Technology and Research Singapore , National University of Singapore
Application Number:	US15/558,937

Details for Patent 10,316,078

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Rare Disease Therapeutics, Inc. (rdt)	ANAVIP	crotalidae immune f(ab')2 (equine)	For Injection	125488	May 06, 2015	10,316,078	2036-03-17

International Patent Family for US Patent 10,316,078

Country	Patent Number	Estimated Expiration
China	107531779
European Patent Office	3271390
Japan	2018514193